Choosing Decentralized Clinical Trials
The Rise of DCTs
The COVID-19 pandemic has challenged the viability of traditional clinical trials around the world. The use of decentralized clinical trial (DCT) options was on the rise before the pandemic, but the industry’s growing need to keep research moving forward and ensure the safety of clinicians and patients made the need for remote capabilities more important than ever. With new efficiencies produced by telemedicine, remote monitoring, direct-to-patient shipments, devices and more, these new options will remain an important attribute of clinical trials as we enter the digital age of research.
Why Choose DCTs
As the clinical landscape continues to evolve, DCTs present opportunities to emphasize convenience, safety and flexibility, while continuing to pursue quality data and valuable research. Advantages include:
EXAMINING IMPLEMENTATION TIMELINES FOR DECENTRALIZED CLINICAL TRIALS (DCTs)
While DCTs can still enable trials that would otherwise be challenging during the pandemic, many of the potential efficiencies — particularly rapid implementation — can remain out of reach. PPD has DCT strategies built into the protocol from the start, with custom features and functions instead of a one-size-fits-all approach.
Building Decentralized Clinical Trials for Patients and Clinicians
The increased implementation of decentralized clinical trials means the industry now has a considerable body of evidence and experience to test the strengths of digital clinical trial models. With the growing amount of data comes the ability to assess how to make trials more effective and efficient, including a closer look at qualitative sponsor, site and patient feedback. To gain further insight into this transformation, PPD explored the experiences that key stakeholders have had when approaching decentralized clinical trials.
PPD NAMED A LEADER IN DIGITAL CLINICAL TRIAL SOLUTIONS BY ISG
Information Services Group (ISG) recognized PPD in its 2020 ISG Provider Lens™ Life Sciences Digital Services Global Report. The honorees were determined following a nine-month research study, in which providers were independently evaluated. The findings recognize PPD as an ISG Provider Lens Leader for digital transformation services, specifically its clinical development and patient engagement solutions.
Digital Innovation & Implementation
How can PPD’s suite of digital capabilities and solutions help you reach more patients?